The New Jersey-based drugmaker secured a conditional license to protect chickens with its H5N2 subtype vaccine.

In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The ...

Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...

BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...

Investment analysts at William Blair reduced their Q1 2025 EPS estimates for shares of Zoetis in a note issued to investors ...

Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $3,455.90 today based on a ...

Q4 2024 Earnings Call Transcript February 13, 2025 Zoetis Inc. beats earnings expectations. Reported EPS is $1.4, ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Zoetis on Feb. 14 received a conditional license from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus.

Zoetis had good record of retained earnings with an average of $4.38 Billion. Retained earnings are the sum of the current ...